Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2023, with specific data reported as of March 31, 2023. The document serves as a regulatory notification to the market regarding the company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to capital structure details.
| Metric | Value |
|---|---|
| Issued Share Capital (as of March 31, 2023) | 4,312,015,636 Ordinary Shares |
| Share Par Value | 31 1/4 pence each |
| Treasury Shares | 217,068,169 |
| Total Voting Rights | 4,094,947,467 |
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory notification intended to assist shareholders in calculating their notification thresholds under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,094,947,467) to determine if disclosure thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (217,068,169) which are excluded from the voting rights count.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly earnings releases for financial performance data.